0000070318false00000703182024-02-012024-02-010000070318exch:XNYSus-gaap:CommonStockMember2024-02-012024-02-010000070318us-gaap:SeniorNotesMemberexch:XNYS2024-02-012024-02-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
_______________
Date of Report: February 1, 2024
(Date of earliest event reported)
_______________
TENET HEALTHCARE CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nevada |
|
1-7293 |
|
95-2557091 |
| (State of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification Number) |
14201 Dallas Parkway
Dallas, TX 75254
(Address of principal executive offices, including zip code)
(469) 893-2200
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
|
|
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common stock, $0.05 par value |
|
THC |
|
NYSE |
| 6.875% Senior Notes due 2031 |
|
THC31 |
|
NYSE |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
|
|
|
|
| Item 2.01. |
Completion of Acquisition or Disposition of Assets. |
On February 1, 2024, Tenet Healthcare Corporation (the “Company”) announced the completion of the previously announced sale of three of its South Carolina hospitals, affiliated physician practices, and other related operations, (the "Divested Assets"). Affiliates of Novant Health purchased the Divested Assets for a base purchase price of $2.400 billion in cash, which is subject to customary purchase price adjustments (the 'Transaction").
Unaudited pro forma financial information relating to the Transaction is filed in Item 9.01 of this Current Report on Form 8-K.
|
|
|
|
|
|
| Item 7.01. |
Regulation FD Disclosure. |
The Transaction is estimated to result in a pretax gain of approximately $1.7 billion. In addition, the Company estimates that as a result of the pre-tax book gain, the Company's income tax expense would be favorably impacted in 2024 by approximately $150 million due to a reduction in interest expense limitations. Additional information regarding the Transaction is provided in the Current Report on Form 8-K filed by the Company on
November 17, 2023.
The information contained in this Item 7.01 and Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
|
|
|
|
|
| Item 9.01. |
Financial Statements and Exhibits. |
(b) Pro Forma Financial Information
The Company's unaudited pro forma condensed consolidated balance sheet as of September 30, 2023 and unaudited pro forma condensed consolidated statements of operations for the year ended December 31, 2022 and the nine months ended September 30, 2023 (collectively, the "Unaudited Pro Forma Financial Statements") are filed as Exhibit 99.1 hereto and are based on the Company's historical consolidated results of operations and financial position, adjusted to give effect to the Transaction. The unaudited pro forma condensed consolidated balance sheet as of September 30, 2023 has been prepared to present the Company's financial conditions as if the Transaction had occurred on September 30, 2023. The unaudited pro forma condensed statements of operations for the year ended December 31, 2022 and the nine months ended September 30, 2023 have been prepared to present the Company's results of operations as if the Transaction had occurred on January 1, 2022.
The Unaudited Pro Forma Financial Statements and the accompanying notes should be read together with the Company's audited consolidated financial statements and accompanying notes as of and for the year ended December 31, 2022, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and its unaudited condensed consolidated financial statements and accompanying notes as of and for the nine months ended September 30, 2023, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in the Company’s Quarterly Report on Form 10-Q for the nine months ended September 30, 2023.
Cautionary Statement.
This report contains “forward-looking statements”–that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to, the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission.
|
|
|
|
|
|
|
|
|
| Exhibit No. |
|
Description |
| 99.1 |
|
|
|
| 104 |
|
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
TENET HEALTHCARE CORPORATION |
|
|
|
Date: February 1, 2024 |
By: |
/s/ R. SCOTT RAMSEY |
|
|
R. Scott Ramsey |
|
|
Senior Vice President, Controller |
EX-99.1
2
thc-20240201aex991.htm
EX-99.1
Document
TENET HEALTHCARE CORPORATION
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The following unaudited pro forma condensed consolidated financial statements are based on the Company's historical consolidated results of operations and financial position, adjusted to give effect to the Transaction, as defined in Item 2.01 of this Form 8-K, as if it had been completed on September 30, 2023 with respect to the pro forma condensed consolidated balance sheet and as of January 1, 2022 with respect to the pro forma condensed consolidated statements of operations.
These unaudited pro forma condensed consolidated financial statements have been prepared in accordance with Article 11 of Regulation S-X and do not include all of the information and note disclosures required by generally accepted accounting principles of the United States.
The unaudited pro forma condensed consolidated financial information is subject to the assumptions and adjustments described in the accompanying notes. These assumptions and adjustments are based on information presently available. Actual adjustments may differ materially from the information presented. The unaudited pro forma condensed consolidated financial statements are based on the historical financial statements of the Company for each period presented and in the opinion of the Company's management, all adjustments and disclosures necessary for a fair presentation of the pro forma data have been made. These unaudited pro forma condensed consolidated financial statements are presented for illustrative purposes only and are not necessarily indicative of the results of operations or financial condition that would have been achieved had events reflected been completed as of the dates indicated, and may not be useful in predicting the impact of the Transaction on the future financial condition and results of operations of the Company due to a variety of factors.
TENET HEALTHCARE CORPORATION
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
SEPTEMBER 30, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (Dollars in millions) |
|
|
|
Pro Forma |
|
|
|
|
Historical |
|
Adjustments |
|
|
Pro Forma |
| ASSETS |
|
|
|
|
|
|
|
| Current assets: |
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
$ |
1,054 |
|
|
$ |
2,395 |
|
(a) |
|
$ |
3,449 |
|
| Accounts receivable |
|
2,897 |
|
|
(82) |
|
(b) |
|
2,815 |
|
| Inventories of supplies, at cost |
|
413 |
|
|
(11) |
|
(b) |
|
402 |
|
| Income tax receivable |
|
— |
|
|
— |
|
|
|
— |
|
| Assets held for sale |
|
140 |
|
|
— |
|
|
|
140 |
|
| Other current assets |
|
1,855 |
|
|
(23) |
|
(b) |
|
1,832 |
|
Total current assets |
|
6,359 |
|
|
2,279 |
|
|
|
8,638 |
|
| Investments and other assets |
|
3,152 |
|
|
(26) |
|
(b) |
|
3,126 |
|
| Deferred income taxes |
|
4 |
|
|
— |
|
|
|
4 |
|
Property and equipment, at cost, less accumulated depreciation and amortization |
|
6,260 |
|
|
(199) |
|
(b) |
|
6,061 |
|
| Goodwill |
|
10,415 |
|
|
(425) |
|
(b) |
|
9,990 |
|
Other intangible assets, at cost, less accumulated amortization |
|
1,400 |
|
|
(18) |
|
(b) |
|
1,382 |
|
Total assets |
|
$ |
27,590 |
|
|
$ |
1,611 |
|
|
|
$ |
29,201 |
|
|
|
|
|
|
|
|
|
| LIABILITIES AND EQUITY |
|
|
|
|
|
|
|
| Current liabilities: |
|
|
|
|
|
|
|
| Current portion of long-term debt |
|
$ |
141 |
|
|
$ |
(1) |
|
(b) |
|
$ |
140 |
|
| Accounts payable |
|
1,202 |
|
|
(18) |
|
(b) |
|
1,184 |
|
| Accrued compensation and benefits |
|
787 |
|
|
(6) |
|
(b) |
|
781 |
|
| Professional and general liability reserves |
|
264 |
|
|
— |
|
|
|
264 |
|
| Accrued interest payable |
|
273 |
|
|
— |
|
|
|
273 |
|
| Liabilities held for sale |
|
17 |
|
|
— |
|
|
|
17 |
|
| Contract liabilities |
|
86 |
|
|
— |
|
|
|
86 |
|
| Other current liabilities |
|
1,662 |
|
|
(25) |
|
(b) |
|
|
|
|
|
|
640 |
|
(e) |
|
2,277 |
|
Total current liabilities |
|
4,432 |
|
|
590 |
|
|
|
5,022 |
|
| Long-term debt, net of current portion |
|
14,901 |
|
|
(1) |
|
(b) |
|
14,900 |
|
| Professional and general liability reserves |
|
787 |
|
|
— |
|
|
|
787 |
|
| Defined benefit plan obligations |
|
327 |
|
|
— |
|
|
|
327 |
|
| Deferred income taxes |
|
278 |
|
|
(53) |
|
(e) |
|
225 |
|
| Other long-term liabilities |
|
1,684 |
|
|
(24) |
|
(b) |
|
1,660 |
|
Total liabilities |
|
22,409 |
|
|
512 |
|
|
|
22,921 |
|
| Commitments and contingencies |
|
|
|
|
|
|
|
Redeemable noncontrolling interests in equity of consolidated subsidiaries |
|
2,303 |
|
|
— |
|
|
|
2,303 |
|
| Equity: |
|
|
|
|
|
|
|
| Shareholders’ equity: |
|
|
|
|
|
|
|
| Common stock |
|
8 |
|
|
— |
|
|
|
8 |
|
| Additional paid-in capital |
|
4,818 |
|
|
— |
|
|
|
4,818 |
|
| Accumulated other comprehensive loss |
|
(176) |
|
|
— |
|
|
|
(176) |
|
| Retained earnings (deficit) |
|
(436) |
|
|
1,099 |
|
(c) |
|
663 |
|
| Common stock in treasury, at cost |
|
(2,750) |
|
|
— |
|
|
|
(2,750) |
|
| Total shareholders’ equity |
|
1,464 |
|
|
1,099 |
|
|
|
2,563 |
|
Noncontrolling interests |
|
1,414 |
|
|
— |
|
|
|
1,414 |
|
| Total equity |
|
2,878 |
|
|
1,099 |
|
|
|
3,977 |
|
Total liabilities and equity |
|
$ |
27,590 |
|
|
$ |
1,611 |
|
|
|
$ |
29,201 |
|
TENET HEALTHCARE CORPORATION
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pro Forma |
|
|
| (Dollars in millions, except per share amounts) |
|
Historical |
|
Adjustments |
|
2022 |
| Net operating revenues |
|
$ |
19,174 |
|
|
$ |
(534) |
|
(d) |
|
$ |
18,640 |
|
| Grant income |
|
194 |
|
|
— |
|
|
|
194 |
|
| Equity in earnings of unconsolidated affiliates |
|
216 |
|
|
— |
|
|
|
216 |
|
| Operating expenses: |
|
|
|
|
|
|
|
| Salaries, wages and benefits |
|
8,844 |
|
|
(190) |
|
(d) |
|
8,654 |
|
| Supplies |
|
3,273 |
|
|
(83) |
|
(d) |
|
3,190 |
|
| Other operating expenses, net |
|
3,998 |
|
|
(113) |
|
(d) |
|
3,885 |
|
| Depreciation and amortization |
|
841 |
|
|
(19) |
|
(d) |
|
822 |
|
| Impairment and restructuring charges, and acquisition-related costs |
|
226 |
|
|
— |
|
|
|
226 |
|
| Litigation and investigation costs |
|
70 |
|
|
(2) |
|
(d) |
|
68 |
|
| Net gains on sales, consolidation and deconsolidation of facilities |
|
(1) |
|
|
(1,686) |
|
(c) |
|
(1,687) |
|
| Operating income |
|
2,333 |
|
|
1,559 |
|
|
|
3,892 |
|
| Interest expense |
|
(890) |
|
|
1 |
|
(d) |
|
(889) |
|
| Other non-operating income (expense), net |
|
10 |
|
|
— |
|
|
|
10 |
|
| Loss from early extinguishment of debt |
|
(109) |
|
|
— |
|
|
|
(109) |
|
| Income from continuing operations, before income taxes |
|
1,344 |
|
|
1,560 |
|
|
|
2,904 |
|
| Income tax benefit (expense) |
|
(344) |
|
|
(551) |
|
(e) |
|
(895) |
|
| Income from continuing operations |
|
1,000 |
|
|
1,009 |
|
|
|
2,009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Less: Net income available to noncontrolling interests |
|
590 |
|
|
— |
|
|
|
590 |
|
Net income from continuing operations available to Tenet Healthcare Corporation common shareholders |
|
$ |
410 |
|
|
$ |
1,009 |
|
|
|
$ |
1,419 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Earnings per share available to Tenet Healthcare Corporation common shareholders: |
|
|
|
|
|
|
|
| Basic |
|
|
|
|
|
|
|
| Continuing operations |
|
$ |
3.83 |
|
|
|
|
|
$ |
13.27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diluted |
|
|
|
|
|
|
|
| Continuing operations |
|
$ |
3.78 |
|
|
|
|
|
$ |
12.91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted average shares and dilutive securities outstanding (in thousands): |
|
|
|
|
|
|
|
| Basic |
|
106,929 |
|
|
|
|
|
106,929 |
| Diluted |
|
110,516 |
|
|
|
|
|
110,516 |
TENET HEALTHCARE CORPORATION
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (Dollars in millions, except per share amounts) |
|
Historical |
|
Pro Forma Adjustments |
|
Pro Forma |
| Net operating revenues |
|
$ |
15,169 |
|
|
$ |
(412) |
|
(d) |
|
$ |
14,757 |
|
| Grant income |
|
14 |
|
|
— |
|
|
|
14 |
|
| Equity in earnings of unconsolidated affiliates |
|
155 |
|
|
— |
|
|
|
155 |
|
| Operating expenses: |
|
|
|
|
|
|
— |
|
| Salaries, wages and benefits |
|
6,831 |
|
|
(145) |
|
(d) |
|
6,686 |
|
| Supplies |
|
2,659 |
|
|
(65) |
|
(d) |
|
2,594 |
|
| Other operating expenses, net |
|
3,319 |
|
|
(93) |
|
(d) |
|
3,226 |
|
| Depreciation and amortization |
|
654 |
|
|
(15) |
|
(d) |
|
639 |
|
| Impairment and restructuring charges, and acquisition-related costs |
|
84 |
|
|
(1) |
|
(d) |
|
83 |
|
| Litigation and investigation costs |
|
28 |
|
|
(2) |
|
(d) |
|
26 |
|
| Net gains on sales, consolidation and deconsolidation of facilities |
|
(12) |
|
|
— |
|
|
|
(12) |
|
| Operating income |
|
1,775 |
|
|
(91) |
|
|
|
1,684 |
|
| Interest expense |
|
(674) |
|
|
1 |
|
(d) |
|
(673) |
|
| Other non-operating income, net |
|
8 |
|
|
— |
|
|
|
8 |
|
| Loss from early extinguishment of debt |
|
(11) |
|
|
— |
|
|
|
(11) |
|
| Income from continuing operations, before income taxes |
|
1,098 |
|
|
(90) |
|
|
|
1,008 |
|
| Income tax expense |
|
(243) |
|
|
26 |
|
(e) |
|
(217) |
|
| Income from continuing operations |
|
855 |
|
|
(64) |
|
|
|
791 |
|
| Less: Net income available to noncontrolling interests |
|
488 |
|
|
— |
|
|
|
488 |
|
Net income available to Tenet Healthcare Corporation common shareholders |
|
$ |
367 |
|
|
$ |
(64) |
|
|
|
$ |
303 |
|
| Earnings per share available to Tenet Healthcare Corporation common shareholders: |
|
|
|
|
|
|
|
| Basic |
|
|
|
|
|
|
|
| Continuing operations |
|
$ |
3.60 |
|
|
|
|
|
$ |
2.97 |
|
| Diluted |
|
|
|
|
|
|
|
| Continuing operations |
|
$ |
3.41 |
|
|
|
|
|
$ |
2.80 |
|
|
Weighted average shares and dilutive securities outstanding
(in thousands):
|
|
|
|
|
|
|
|
| Basic |
|
101,869 |
|
|
|
|
|
101,869 |
| Diluted |
|
105,021 |
|
|
|
|
|
105,021 |
NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(a) Adjustment to reflect cash consideration received from the Transaction of approximately $2,400 million net of $5 million in transaction costs.
(b) Adjustment to eliminate the assets and liabilities attributable to the Divested Assets.
(c) Adjustment reflects the gain on sale from the Transaction, calculated as follows:
|
|
|
|
|
|
| Cash received |
$ |
2,400 |
|
| Transaction costs |
(5) |
|
| Net book value of Divested Assets |
(284) |
|
| Goodwill allocated to the sale |
(425) |
|
| Pro forma gain before income taxes |
1,686 |
|
| Provision for income taxes |
(587) |
|
| Pro forma net gain on sale |
$ |
1,099 |
|
This adjustment is not expected to recur in income of the Company beyond 12 months from the Transaction.
(d) Adjustment to eliminate the historical revenue and operating expenses of the Divested Assets including expenses of $1 million related to the Transaction recorded in the nine months ended September 30, 2023. Adjustments do not include general corporate overhead or other costs previously allocated to the facilities sold if they are expected to recur in income of the Company beyond 12 months from the Transaction.
(e) Adjustment reflects the applicable income tax effects of $551 million from the Transaction. Approximately $587 million relates to the gain on sale and $36 million and $26 million relates to the eliminations set forth in Note (d) for the year ended December 31, 2022 and the nine months ended September 30, 2023, respectively. Current liabilities also reflects an adjustment for $640 million of taxes payable on the gain. These adjustments are not expected to recur in income of the Company beyond 12 months from the Transaction.
エドガーで原本を確認する